What one share of Virax Biolabs Group holds
Virax Biolabs Group Limited is a holding company incorporated as an exempted company under the laws of the Cayman Islands. As a holding company with no material operations of its own, we conduct substantially all of our operations through subsidiaries in the United Kingdom, the United States and China.
Virax Biolabs Group’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2026-03-31; the balance sheet is as of 2026-03-31.
| Sales | $0.03 |
|---|---|
| Profit | −$12.64 |
| Capex (buildings and equipment) | $0.64 |
| Free cash flow | −$12.27 |
| Cash and investments | $11.12 |
| Book value | $13.08 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | $0.00 | −$44.67 | — | — | — | −$24.42 |
| 2023 | $0.20 | −$128.35 | — | — | — | $146.75 |
| 2024 | $1.95 | −$83.90 | $11.87 | −$91.57 | — | $52.13 |
| 2025 | $0.04 | −$40.62 | $4.05 | −$34.63 | — | $32.80 |
| 2026 | $0.03 | −$12.64 | $0.64 | −$12.27 | — | $13.08 |
Common questions about Virax Biolabs Group
How much does one share of Virax Biolabs Group earn?
Over its latest fiscal year, Virax Biolabs Group lost $12.64 for each share on $0.03 of sales.
Does Virax Biolabs Group pay a dividend?
Virax Biolabs Group didn’t pay a dividend over its latest fiscal year, according to its SEC filings.
What is Virax Biolabs Group’s book value per share?
Virax Biolabs Group’s book value is $13.08 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of March 31, 2026.
How much cash and debt does each share of Virax Biolabs Group have?
Each share of Virax Biolabs Group has $11.12 of cash and investments, as of March 31, 2026.
What is Virax Biolabs Group’s free cash flow per share?
−$12.27 per share over its latest fiscal year. Free cash flow is the cash left over after spending on buildings and equipment.
Has Virax Biolabs Group bought back shares?
Virax Biolabs Group’s share count rose about 939% from 2022 to 2026. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.